Format

Send to

Choose Destination
Diabetes Res Clin Pract. 2018 Aug;142:335-344. doi: 10.1016/j.diabres.2018.06.002. Epub 2018 Jun 11.

Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.

Author information

1
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, South Korea.
2
Department of Plastic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
3
Department of Plastic Surgery, Korea University Guro Hospital, Seoul, South Korea.
4
Department of Orthopaedic Surgery, School of Medicine, Ajou University, Suwon, South Korea.
5
Department of Orthopaedic Surgery, Inha University College of Medicine, Incheon, South Korea.
6
Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
7
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: ljwos@yuhs.ac.

Abstract

AIMS:

This study was conducted to evaluate the efficacy and safety of a novel spray-applied growth factor therapy containing recombinant human epidermal growth factor (rhEGF) for the treatment of chronic diabetic foot ulcers (DFU).

METHODS:

This study was a phase III double-blind, randomized, placebo-controlled trial. 167 adult patients at six medical centers were randomized to receive routine wound care plus either topical spray treatment with 0.005% rhEGF (n = 82) or an equivalent volume of saline spray (n = 85) twice a day until ulcer healing or for up to 12 weeks.

RESULTS:

Demographics, medical status, and wound characteristics were comparable between rhEGF and placebo groups. More patients in the rhEGF group significantly had complete wound healing compared to placebo (73.2% versus 50.6%, respectively; P = .001). Wound healing velocity was faster in the rhEGF group (P = .029) regardless of HbA1c levels. The rhEGF group had a shorter median time to 50% ulcer size reduction (21 versus 35 days; hazard ratio = 3.13, P < .001) and shorter time to complete ulcer healing (56 versus 84 days; hazard ratio = 2.13, P < .001).

CONCLUSIONS:

This study confirms that application of spray-applied rhEGF in DFU patients results in faster healing velocity and higher complete healing rate regardless of HbA1c levels.

KEYWORDS:

Diabetic foot ulcer; Epidermal growth factor; Hemoglobin A1c; Wound healing

PMID:
29902542
DOI:
10.1016/j.diabres.2018.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center